ArriVent goes Further into PACC mutations
The group is aiming for accelerated approval with the upcoming Alpacca trial.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The first global pivotal trial will be in first-line triple-negative breast cancer.
The group expects to raise nearly $170m.